NorthEast Community Bancorp, Inc. Announces Quarterly Cash Dividend
About NorthEast Community Bancorp, Inc.
NorthEast Community Bancorp, headquartered at 325 Hamilton Avenue, White Plains, New York 10601, is the holding company for NorthEast Community Bank, which conducts business through its eleven branch offices located in Bronx, New York, Orange, Rockland, and Sullivan Counties in New York and Essex, Middlesex, and Norfolk Counties in Massachusetts and three loan production offices located in New City, New York, White Plains, New York, and Danvers, Massachusetts. For more information about NorthEast Community Bancorp and NorthEast Community Bank, please visit www.necb.com.
Cautionary Note About Forward-Looking Statements
This press release contains certain forward-looking statements. Forward-looking statements include statements regarding anticipated future events and can be identified by the fact that they do not relate strictly to historical or current facts. They often include words such as 'believe,' 'expect,' 'anticipate,' 'estimate,' and 'intend' or future or conditional verbs such as 'will,' 'would,' 'should,' 'could,' or 'may.' These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements as a result of numerous factors. Factors that could cause actual results to differ materially from expected results include, but are not limited to, changes in market interest rates, regional and national economic conditions (including higher inflation and its impact on regional and national economic conditions), legislative and regulatory changes, monetary and fiscal policies of the United States government, including policies of the United States Treasury and the Federal Reserve Board, the quality and composition of the loan or investment portfolios, demand for loan products, decreases in deposit levels necessitating increased borrowing to fund loans and securities, competition, demand for financial services in NorthEast Community Bank's market area, changes in the real estate market values in NorthEast Community Bank's market area, the impact of failures or disruptions in or breaches of the Company's operational or security systems, data or infrastructure, or those of third parties, including as a result of cyberattacks or campaigns, and changes in relevant accounting principles and guidelines. Additionally, other risks and uncertainties may be described in our annual and quarterly reports filed with the U.S. Securities and Exchange Commission (the 'SEC'), which are available through the SEC's website located at www.sec.gov. These risks and uncertainties should be considered in evaluating any forward-looking statements and undue reliance should not be placed on such statements. Except as required by applicable law or regulation, the Company does not undertake, and specifically disclaims any obligation, to release publicly the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of the statements or to reflect the occurrence of anticipated or unanticipated events.
CONTACT:
Kenneth A. Martinek
Chairman and Chief Executive Officer
PHONE:
(914) 684-2500
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million. TD Cowen and BMO Capital Markets acted as joint book-running managers for the offering. The shares of common stock were offered by Prime Medicine pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023 and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 West 42nd Street, 32nd Floor, New York, New York 10036, by email at bmoprospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Prime Medicine Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path. Investor and Media ContactsGregory DearbornPrime Medicine857-209-0696gdearborn@ Hannah DeresiewiczPrecision
Yahoo
20 minutes ago
- Yahoo
SITE Centers Announces Two Sales and Special Common Distribution
BEACHWOOD, Ohio, August 01, 2025--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC) announced today the sale of Winter Garden Village (Orlando, FL) for $165.0 million and the sale of Deer Valley Towne Center (Phoenix, AZ) for $33.7 million, both prior to closing costs, prorations and other closing adjustments. A portion of net proceeds were used to repay $22.3 million of mortgage debt. The Company's Board of Directors also declared a special cash distribution on its common shares of $3.25 per common share payable on August 29, 2025 to shareholders of record at the close of business on August 15, 2025. Because the payment of the special dividend represents more than 25% of the price of the Company's common shares, NYSE has advised the Company that its common shares will trade with "due bills" representing an assignment of the right to receive the special dividend from the record date of August 15, 2025 through the closing of trading on NYSE on August 29, 2025, which is the payment date and the last day of trading before the September 2, 2025 ex-dividend date (this period of time representing the "Dividend Right Period"). Shareholders who sell their common shares during the Dividend Right Period will be selling their right to the special dividend, and such shareholders will not be entitled to receive the special dividend. Due bills obligate a seller of common shares to deliver the special dividend payable on such common shares to the buyer (the "Dividend Right"). The record date of August 15, 2025 will be used as the date for establishing the due bill tracking of the Dividend Right to the holder of common shares. Due bill obligations are customarily settled between the brokers representing the buyers and the sellers of shares. The Company has no obligation for either the amount of the due bill or the processing of the due bill. Buyers and sellers of the Company's common shares should consult their brokers before trading to be sure they understand the effect of NYSE's due bill procedures. About SITE Centers Corp. SITE Centers is an owner and manager of open-air shopping centers located primarily in suburban, high household income communities. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC. Additional information about the Company is available at To be included in the Company's e-mail distributions for press releases and other investor news, please click here. View source version on Contacts For additional information:Gerald Morgan, EVP andChief Financial Officer216-755-5500 Sign in to access your portfolio
Yahoo
20 minutes ago
- Yahoo
Why Figma Stock Skyrocketed 250% This Week
Key Points Figma stock surged 247% after its IPO, hitting a market cap close to $60 billion. Impressive recent growth (more than 40% YOY) and widespread adoption highlight the platform's strength. At this valuation, investors must believe Figma can sustain rapid growth and fend off intensifying AI-driven competition. 10 stocks we like better than Figma › Shares of Figma (NYSE: FIG) exploded this week after its public debut on Thursday. The stock is currently trading 253% higher than its initial public offering (IPO) price as of 3:17 p.m. ET. The extreme leap comes as the S&P 500 lost 2.4%, and the Nasdaq-100 lost 2.2% amid new tariffs and weak jobs data. Figma, which offers a web-based design platform that is used to create websites and apps, IPOed on Thursday at $33 a share and is now trading above $118. The huge IPO eclipsed even the recent success of Circle Internet, which saw its stock triple in the first few weeks. Figma's stock is red hot The company has now reached a valuation of nearly $60 billion. That is a pretty hefty valuation, given the company's 2024 sales of under $750 million. Granted, it has grown its top line by more than 40% in both of the last two years. That's pretty impressive. I have doubts, however, about how long this trajectory can last. The company touts that "95% of the Fortune 500" used Figma in March of this year. While that number lends clout to the company and the quality of its product, it's a double-edged sword. It calls into question how much the company can continue growing its enterprise revenue if it is already so ubiquitous among the most important companies in the world. I have serious doubts about the strength of Figma's moat and its ability to defend it in a hyper-competitive landscape actively being transformed by artificial intelligence (AI), at least at its current valuation. It would need to continue to deliver 40% growth for years to justify its current valuation and continue to offer investors a solid return. Should you buy stock in Figma right now? Before you buy stock in Figma, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Figma wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Figma Stock Skyrocketed 250% This Week was originally published by The Motley Fool
